Status:

RECRUITING

Immunosuppression and COVID-19 Boosters

Lead Sponsor:

Kirby Institute

Collaborating Sponsors:

Seqirus Pty Ltd, Australia

Medical Research Future Fund

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

It is important people receiving immunosuppressive therapy are provided with the best protection against COVID-19 because they are at greater risk of severe illness should they become infected. As sev...

Detailed Description

Current guidelines for SARS-CoV2 vaccination in immunosuppressed populations are based on limited evidence. Additionally, guidelines for the use of SARS-CoV2 vaccines in autoimmune populations are som...

Eligibility Criteria

Inclusion

  • Adult aged at least 18 years
  • Previously vaccinated with 2 (or more) doses of any licensed COVID-19 vaccine who requires initiation of moderate-to-severe immunosuppression; most recent COVID-19 vaccine dose must have been given \> 3 months prior
  • Planned significant immunosuppressive therapy for at least 1 year
  • No cyclophosphamide, alemtuzumab or rituximab treatment in the past 5 years. Note: patient may have concurrent steroids with any treatments listed in protocol
  • Voluntarily given written informed consent

Exclusion

  • Pregnant or breastfeeding
  • Has underlying primary immunodeficiency
  • Has received or likely to receive intravenous/subcutaneous immunoglobulin (IVIg/ScIg).
  • Projected treatment is likely to involve plasma exchange
  • Contraindication to receipt of SARS-CoV-2 vaccine
  • Intolerance of or previous allergic reaction to tetanus vaccination
  • Patients switching immunosuppressive therapies following enrolment with an absolute lymphocyte count \<0.5 x 109/L immediately prior to screening

Key Trial Info

Start Date :

July 21 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2026

Estimated Enrollment :

320 Patients enrolled

Trial Details

Trial ID

NCT05415267

Start Date

July 21 2023

End Date

December 31 2026

Last Update

July 25 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Blacktown Hospital

Blacktown, New South Wales, Australia, 2148

2

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia, 2050

3

Concord General Repatriation Hospital

Concord, New South Wales, Australia, 2137

4

St Vincent's Hospital, Sydney

Darlinghurst, New South Wales, Australia, 2010